找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Immunology; Bench to Bedside Imm Nima Rezaei Book 20151st edition Springer-Verlag Berlin Heidelberg 2015 Cancer immunology.Cancer im

[復(fù)制鏈接]
樓主: Coarse
41#
發(fā)表于 2025-3-28 16:55:42 | 只看該作者
f cancers, with a focus on clinical aspects.Describes in depThis translational book describes in detail the clinical application of novel approaches in cancer immunotherapy with the aim of educating clinicians in the implications of the most recent research and new developments in the field. The sco
42#
發(fā)表于 2025-3-28 20:50:49 | 只看該作者
43#
發(fā)表于 2025-3-29 01:23:19 | 只看該作者
44#
發(fā)表于 2025-3-29 05:30:39 | 只看該作者
45#
發(fā)表于 2025-3-29 10:44:54 | 只看該作者
Monoclonal Antibodies for Cancer Immunotherapy,rapeutic mAbs entails gaining in-depth knowledge about factors including antibody structure and function, the properties of an ideal tumor antigen, the advantages of employing combinational therapies, and the limitations of antibody-based modalities. This chapter concentrates on mAbs as versatile platforms for cancer immunotherapy.
46#
發(fā)表于 2025-3-29 12:18:04 | 只看該作者
Book 20151st editionin the implications of the most recent research and new developments in the field. The scope is broad, encompassing, for example, prognostic biomarkers for personalized cancer treatment, strategies for targeting tumor immunosuppression, gene therapy, virus-based vaccines, targeting of cancer stem ce
47#
發(fā)表于 2025-3-29 19:07:26 | 只看該作者
Ger J. van der Vusse,Robert S. Renemantherapeutic options to a broad range of malignancies. This chapter will review the rationale for targeting immune checkpoints, the pathways of particular interest, and the research being conducted to bring checkpoint blockade to clinical use.
48#
發(fā)表于 2025-3-29 23:34:33 | 只看該作者
49#
發(fā)表于 2025-3-29 23:58:50 | 只看該作者
Overcoming Cancer Tolerance with Immune Checkpoint Blockade,therapeutic options to a broad range of malignancies. This chapter will review the rationale for targeting immune checkpoints, the pathways of particular interest, and the research being conducted to bring checkpoint blockade to clinical use.
50#
發(fā)表于 2025-3-30 05:42:10 | 只看該作者
Toll-Like Receptor Pathway and its Targeting in Treatment of Cancers,e TLR function varies according to the cancer type and the TLRs expressed, their signaling pathway should either be triggered or targeted to control cancer progression. Hence, more investigations are required to discover proper therapeutic approaches for cancer.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 16:00
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
阜新市| 博爱县| 锦屏县| 安宁市| 夹江县| 绥滨县| 察哈| 潞城市| 麻阳| 太仓市| 汨罗市| 丹棱县| 米泉市| 泽普县| 尚志市| 万载县| 南漳县| 彝良县| 民乐县| 安顺市| 泸州市| 仪陇县| 绥中县| 呼和浩特市| 浪卡子县| 山阳县| 资源县| 建德市| 宝兴县| 鹤山市| 通道| 诏安县| 义马市| 灵武市| 沛县| 莒南县| 措勤县| 大庆市| 定陶县| 新田县| 安西县|